| ObjectiveThis is a study which randomized controlled was used to observe the clinical efficacy of Yiqi Huoxue Powder for the secondary prevention of cerebral infarction in the convalescent period,laying a foundation for the further application of traditional Chinese medicine in the secondary prevention of clinical cerebral infarction in the convalescent period,and providing a safe and effective new idea for the secondary prevention of clinical cerebral infarction.MethodsThis experiment by collecting conforms to the inclusion criteria of a total of 62 patients with cerebral infarction convalescence,age distribution from 40 to 75 years old.By using the random number table method,the enrolled cases were randomly assigned to the treatment group and the control group,and 31 cases were assigned to the treatment group and the control group in the end.In the control group,according to the ischemic stroke and transient ischemic attack secondary prevention guide(2014 edition)shall be the Aspirin enteric coated tablets + Atorvastatin calcium tablets for secondary prevention,and according to their own specific circumstances,positive control of blood pressure,blood sugar,blood fat reducing risk factors such as.The Yiqi Huoxue Powder,was given to the treatment group on the basis of the treatment in the control group,which was a kind of oral traditional Chinese medicine.After 6 months of continuous drug treatment,the efficacy and safety were evaluated.Then,the recurrence rate and the difference of scale scores before and after treatment wold be compared between the two groups.The data in this study were statistically analyzed by SPSS24.0.Results1.In the treatment group,there was 1 case of recurrent stroke,and the recurrence rate was 3.3%.In the control group,there were 3 cases of recurrent stroke,and the recurrence rate of stroke was 10.0%.After statistical test of data,the P>0.05 showed no statistically significant difference in the recurrence rate between the treatment group and the control group.The recurrence rate of the treatment group was not significantly superior to that of the control group.2.Score comparison in NIHSS: Before the treatment,intra-group comparisons were made between the two groups,and the results were statistically significant(P<0.05).The results were same in 90 days after treatment and 180 days after treatment between two groups in group intra comparisons.There was statistically significant difference between the two groups after 90 days and 180 days of treatment(P < 0.05).3.Score comparison in BI: The treatment group was compared within the group,and the differences were statistically significant(P<0.05),after the statistical test.In the control group,intra-group comparisons were made before treatment(baseline)and 90 days after treatment,and before treatment(baseline)and 180 days after treatment,and the differences were statistically significant(P<0.05)through statistical test.There was no statistical significance between 90 days of treatme nt and 180 days of treatment(P>0.05).Comparison were made between the treatment group and the control group before treatment(baseline),and the difference between the two groups was statistically tested and P>0.05,which was not statistically significant.After 90 days of treatment,the difference was statistically tested and P>0.05,which was not statistically significant.After 180 days of treatment,the difference was statistically significant,P<0.05,according to the statistical test.4.Score comparison in mRS: The treatment group was compared within the group,and the difference was statistically significant,P<0.05,according to the statistical test.The control group was compared within the group,after statistical test,and the difference was statistically significant,P<0.05.Between the treatment group and the control group,the comparison was maded before treatment(baseline),and the difference between the two groups was statistically tested and P>0.05,which was not statistically significant.After 90 days of treatment,the difference was statistically tested and P>0.05,which was not statistically significant.After 180 days of treatment,the difference was statistically significant,P<0.05,according to the statistical test.5.The safety of the two groups was good,and no adverse reactions were observed.Conclusion1.The application of Yiqi Huoxue Powder in the treatment of secondary prevention of cerebral infarction convalescence cannot reduce the recurrence rate of cerebral infarction convalescence.2.Yiqi huoxue powder can improve the neurological function deficit(NIHSS score)i n patients with cerebral infarction convalescence,which is significantly different from the application of basic secondary prevention(Aspirin enteric coated tablets + Atorvastatin calcium tablets).3.The application of Yiqi Huoxue Powder can improve the degree of disability of patients with cerebral infarction convalesce(BI score and MRS scale),but it needs long-term use(180 days of treatment),and its efficacy is superior to the application of basic secondary prevention(Aspirin +Atorvastatin).4.Using Yiqi huoxue powder can be safe. |
PDF Full Text Request